Latham & Watkins Advises on Verrica Pharmaceuticals’ US$50 Million Private Placement Financing

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, has announced that it has entered into a series of securities purchase agreements for a private investment in public equity (PIPE) financing, raising approximately US$50 million in gross proceeds, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about November 25, 2025, subject to satisfaction of customary closing conditions.

Latham & Watkins LLP is advising the placement agent in the financing with a Capital Markets team led by New York partners Nathan Ajiashvili and Salvatore Vanchieri, with associate Vanessa Hillabrand and assistance from Chanie Saltzman.